Bristol Myers Squibb has expanded Opdivo’s first-in-class win in pre-surgery non-small cell lung cancer, teeing up a potential FDA filing. Opdivo added to chemotherapy before …
It wasn’t long ago that Bristol Myers Squibb ran the numbers on potentially buying Acceleron Pharma, but that deal didn’t come together, and the biotech …
As officials in Washington weigh contentious drug-pricing measures, there’s even more evidence that pharma companies are worried about potential reform. In an open letter to …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
